Literature DB >> 32523266

A Randomized Trial Comparing the Efficacy of Methylene Blue Dye Alone Versus Combination of Methylene Blue Dye and Radioactive Sulfur Colloid in Sentinel Lymph Node Biopsy for Early Stage Breast Cancer Patients.

Vikas Gupta1, Kvvn Raju1, T Subramanyeshwar Rao1, C K Naidu1, Vipin Goel1, Nisha Hariharan1, Ramachandra Nagarajuch1, B Madhunarayana1.   

Abstract

Although sentinel lymph node biopsy (SLNB) has become a standard of care for management of axilla in breast cancer patients, the technique of SLNB is still not well defined. Unlike radioactive sulfur colloid which requires nuclear medicine facilities, methylene blue dye is readily available. The purpose of this study is to validate the use of methylene blue dye alone for SLNB in early breast cancer patients. 60 patients of early breast cancer were randomized to receive either methylene blue alone (Group A-30 patients) or a combination of both methylene blue and radioactive colloid (Group B-30 patients) for detection of sentinel lymph nodes. Sentinel lymph node biopsy was done followed by complete axillary dissection in all patients. In both Groups A and B, sentinel node was identified in all 30 patients, giving identification rate of 100%. In group A, sentinel node was the only positive node in 1 patient, with a false-positive rate of 14.2%. The negative predictive value was 91.3%. The sensitivity of the procedure in predicting further axillary disease was 75% with a specificity of 95.45%. The overall accuracy was 90%. In group B, sentinel node was the only positive node in 2 cases, giving a false-positive rate of 28.7%. The negative predictive value was 95.65%. The sensitivity of the procedure in predicting further axillary disease was 83.33% with a specificity of 91.67%. The overall accuracy was 90%. Although the false-negative rate was slightly higher with methylene blue alone than that using combination (8.6%-4.3%), it was statistically insignificant. Similarly the sensitivity (75%-83.33%), specificity (95.45-91.67%), and negative predictive value (91.3%-95.67%) were also comparable between groups A and B, respectively. Negative predictive value and false-negative rates are comparable, whether blue dye is used alone or a combination of blue dye and radioactive colloid is used. Sentinel lymph node biopsy with blue dye alone is reliable and can be put to clinical practice more widely, even if nuclear medicine facilities are not available in resource constrained centers, so as to reduce long-term morbidity of axillary dissection, with similar oncological outcomes. © Indian Association of Surgical Oncology 2019.

Entities:  

Keywords:  Blue dye; Breast cancer; Radioactive colloid; Sentinel

Year:  2019        PMID: 32523266      PMCID: PMC7260306          DOI: 10.1007/s13193-019-01023-3

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  35 in total

1.  Sentinel node in breast cancer--a Swedish pilot study of 75 patients.

Authors:  J Frisell; L Bergqvist; G Liljegren; M Thörn; S Damm; H Rydman; R Danielsson
Journal:  Eur J Surg       Date:  2001-03

2.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes.

Authors:  U Veronesi; G Paganelli; V Galimberti; G Viale; S Zurrida; M Bedoni; A Costa; C de Cicco; J G Geraghty; A Luini; V Sacchini; P Veronesi
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

3.  National practice patterns of sentinel lymph node dissection for breast carcinoma.

Authors:  A Lucci; P R Kelemen; C Miller; L Chardkoff; L Wilson
Journal:  J Am Coll Surg       Date:  2001-04       Impact factor: 6.113

4.  Axillary ultrasound and fine-needle aspiration in the preoperative evaluation of the breast cancer patient: an algorithm based on tumor size and lymph node appearance.

Authors:  Martha B Mainiero; Christina M Cinelli; Susan L Koelliker; Theresa A Graves; Maureen A Chung
Journal:  AJR Am J Roentgenol       Date:  2010-11       Impact factor: 3.959

5.  Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes.

Authors:  K M McMasters; S L Wong; T M Tuttle; D J Carlson; C M Brown; R Dirk Noyes; R L Glaser; D J Vennekotter; P S Turk; P S Tate; A Sardi; M J Edwards
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

6.  Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.

Authors:  H H Hartgrink; C J H van de Velde; H Putter; J J Bonenkamp; E Klein Kranenbarg; I Songun; K Welvaart; J H J M van Krieken; S Meijer; J T M Plukker; P J van Elk; H Obertop; D J Gouma; J J B van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus; M Sasako
Journal:  J Clin Oncol       Date:  2004-04-13       Impact factor: 44.544

7.  Comparison of vital dye-guided lymphatic mapping and dye plus gamma probe-guided sentinel node biopsy in breast cancer.

Authors:  Gábor Cserni; Mária Rajtár; Gábor Boross; Mária Sinkó; Mihály Svébis; Béla Baltás
Journal:  World J Surg       Date:  2002-03-01       Impact factor: 3.352

8.  Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.

Authors:  David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

Review 9.  Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data.

Authors:  James E Gervasoni; Samer Sbayi; Blake Cady
Journal:  Ann Surg Oncol       Date:  2007-06-28       Impact factor: 5.344

10.  Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients.

Authors:  C L Slingluff; K R Stidham; W M Ricci; W E Stanley; H F Seigler
Journal:  Ann Surg       Date:  1994-02       Impact factor: 12.969

View more
  3 in total

1.  Assessment of Intraparenchymal Injection of 1% Patent Blue Dye in the Upper Outer Quadrant of the Breast to Identify Sentinel Lymph Node in Early Retro-Areolar Breast Cancer in Women: A Tertiary Centre Experience in Egypt.

Authors:  Mina M B Fouad; Kirilos Fouad; Sandy M N Ibraheim
Journal:  World J Surg       Date:  2022-01-07       Impact factor: 3.352

2.  Validation sentinel lymph node biopsy study in cN0 axilla using low-cost dual dye technique: potential solution for resource poor settings.

Authors:  Jayesh Chavda; Arpan Mishra; Ashutosh Silodia; Sanjay Kumar Yadav; Deepti Bala Sharma; Dhananjaya Sharma; Muktesh Khandare
Journal:  Breast Cancer Res Treat       Date:  2022-03-05       Impact factor: 4.872

3.  The detection rate of methylene blue combined with another tracer in sentinel lymph node biopsy of early-stage breast cancer: a systematic review and network meta-analysis.

Authors:  Hong-Jin Liu; Ming-Shuai Sun; Li-Yuan Liu; Zheng-Heng Yu; Xiao-Xi Chen; Qian Liu; Yuan-Jia Cheng; Ling Xu; Yin-Hua Liu; Jing-Ming Ye
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.